Hepatitis and hepatic fibrosis prevent
liver cancer alternative : Gycyrrhizin
1 . Promote liver function
(GPT, GOT, TB) returned to normal, liver histology (Histology)
improved.(2) reduce
liver cancer incidence rate 50 ~ 60% (Cancer 1997, Oncology 2002 ─ 15 years of
long-term studies ) .3 patients with
interferon invalid , you can still reduce the rate of liver cancer 49% (Dig.
Dis. And Sci. 2006).
Efficacy against
Hepatitis B :
Within four weeks of
liver function improvement rate chart
Significantly reduce the inflammation of the liver
index , the effective rate of 78% or more:109 chronic hepatitis B patients , the
use of four weeks , a significant improvement in liver function
.ALT levels ─ the effect of 51% ,
effective 78%.AST levels ─ the
efficiency 59% , effective 83%.TB
value ─ the effect of 36% , effective 64%.( Reference : Hepatology research
2000.)
Within eight weeks
of liver function improvement rate chart
194 chronic hepatitis B
patients , the use of eight weeks with different doses (100mL,
40mL).ALT values
<1 .5x="" .="" 74="" 79="" br="" uln="" were="">1>ALT levels <40 .="" 57="" 58="" br="" iu="" l="" were="">40>─ improved symptoms of
hepatitisJaundice disappeared, spirit,
appetite , sleep quality improved.Eliminate
fatigue , bloating disappear.─ safe, no
side effects, long-term use90% of
patients had no adverse effects occurThe effect ─ ALT, AST,
TB (Total bilirubin) <1 .5="" br="" disappears.="" jaundice="" normal="" times="">1>Effective ─ including the aforementioned lower
values less than 50% improvement in symptoms in patients .( Reference : Hepatology research
2000, 2002.)
Efficacy against Hepatitis C :
Reduced rate of liver cancer fifteen years
─ cirrhosis, liver cancer incidence by 50 to
60%403 CHC
patients , the use of Glycyrrhizin up to 15 years , proven to reduce cirrhosis
(Cirrhosis) and the incidence of hepatocellular carcinoma (HCC).F1 reduced the incidence of
liver cancer patients 50% (6% vs. 12%, n = 193, p = 0.040).F2 reduced the incidence
of liver cancer patients 53% (15% vs. 32%, n = 128, p = 0.005).F3 decreased incidence of
liver cancer patients 21% (40% vs. 51%, n = 74, p = 0.071).High-risk
group ( > 50 years old , F3) if the ALT value control less than 75 IU / L,
which reduced the incidence of hepatocellular carcinoma 66% (n = 31, p =
0.057).( Reference : Oncology
2002.)
Reduced rate of liver cancer
fifteen years
─ also effective than
interferon ?Analysis of chronic
hepatitis C , interferon treatment group of 1191 , the use of Glycyrrhizin
treatment group were 453 .Interferon (IFN) treatment
group compared with the control group, the incidence of liver cancer decreased
33% (n = 1191, p = 0.14).Glycyrrhizin
treatment group, the incidence of liver cancer compared with the control group
decreased 60% (n = 453, p = 0.044, Multivariate analysis using time ≧ 10 years ,
1970 ~ 1984 Kenji Ikeda, MD)(
Reference : APASL 2002.)
Main
Ingredients:Each
mL of Glycyrrhizinate monoammonium 2.04mg ( equivalent Glycyrrhizin 2.0mg), each
ampoule 20mL.
Dose:Intravenous injection , once a day ,
every 2 to 3 ampoules , continuous injection of 2 to 4 weeks. If ALT unable fell
60 IU / L or less, increase to once a day , every five ampoules , for 2 to 4
weeks , the maximum daily dose of 5 ampoules .
Maintenance dose:If ALT dropped 60 IU / L or
less, 2 to 3 times per week , every 2 to 3 ampoules ; and increase or decrease
the dose according to the disease .
Indications:Maintenance of normal liver function ,
drug allergy, food allergy ; applicable chronic B, C hepatitis patients
.→
interferon (IFN) combined class nuclear drugs (NRTI, ex: Lamivudine or
Ribavirin) ineffective treatment (Non-responder) or re- recurrence
(Relapser).→
intolerable side effects of interferon or class of nuclear medicines for
patients (Side effects)→ expected poor efficacy (CHC
Genotype1, 4, 5, 6) of the patients with chronic hepatitis C→ disease considerations can not use IFN + NRTI
therapy such as :
Decompensated
liver disease ( if jaundice, ascites , hepatic coma ) .Autoimmune diseases such as : rheumatoid
arthritis , psoriasis , autoimmune hepatitis.Immunosuppressants user .Elderly ( > 50 years ) .Depression, anxiety , insomnia.Alcoholic hepatitis .Hematopoietic
function problems .Kidney disease .Anemia.Diabetes.Cardiovascular disease.Thyroid
dysfunction .
Side effects:Safe,
almost no side effects, however still need to pay attention to pseudo- sexual
aldehyde tallow alcohol hyperparathyroidism (Pseudo-aldosteronism) resulting
from sodium retention , hypokalemia , hypertension , clinical manifestations of
lower extremity edema, poor muscle strength , muscle pain, headaches, other side effects such as :
tiredness , abnormal sensation , skin rash.